ALGN
Align Technology, Inc.
$150.49
+1.00% 2026-10-20
Health CareS&P 500
ALGNSPY
1W
+4.8%
1M
+2.0%
3M
-15.2%
6M
-22.9%
YTD
-3.6%
1Y
+11.5%
Live chart
Loading live chart…
Grades vs sector
Momentum37th pct in sectorC-
Momentum
37th pct in sector
12-1 return: +5.4%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Growth23rd pct in sectorD
Growth
23rd pct in sector
Revenue growth (YoY): +4.3%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Value78th pct in sectorB+
Value
78th pct in sector
Forward E/P: 8.4% · EBITDA/EV: 9.8%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
Profitability54th pct in sectorC+
Profitability
54th pct in sector
Profit margin: +10.0% · Return on equity: +10.2%
Percentile within its GICS sector across the S&P 1500.
Percentile within its GICS sector across the S&P 1500.
RevisionsNot enough data yet–
Revisions
Not enough data yet
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
30-day change in analysts' current-year EPS estimate; graded across covered stocks.
Our models
Not held by any of our 5 live models right now.
Quality Growth
not ranked (outside this model's universe or screens)
Momentum Top 15rank 148 of 499 · 12-1 momentum % 27.6
Momentum Blendnot in the current book
New Highs Growthnot ranked (outside this model's universe or screens)
Conviction 20not in the current book
News
More newsGlobal Clear Aligners Market Size, Share, Trends, and Forecast to 2031 | Image-Conscious Adults Set to Nearly Double the Clear Aligner Market to $11bn Market Value
GlobeNewswire · 18h ago
What You Need To Know Ahead of Align Technology's Earnings Release
Barchart · 19h ago
Align Technology Wins Patent Infringement Case Against Angelalign
MT Newswires · Oct 19
Align Technology Wins Significant Patent Infringement Case Against Angelalign at Unified Patent Court
Business Wire · Oct 16
Here Are Thursday’s Top Wall Street Analyst Research Calls: AngloGold Ashanti, Bank of America, Cirrus Logic, Crocs, Diamondback Energy, Devon Energy, Netflix, PayPal, Spotify Technolgy , and More
24/7 Wall St. · Oct 15
Key stats
Market cap$10.7B
P/E (trailing)26.2
P/E (forward)12.1
52-week range130.23 – 200.44
Revenue growth (YoY, latest qtr)+4.3%
Dividend yield0.00%
Analyst consensusBuy (14)
Mean price target$193.79 (+29%)
Valuation and fundamentals
Valuation & fundamentals
Bottom line
Leans undervalued
Model read-out from the numbers below, not advice. Score +1 (DCF counts double).
▼DCF (base case)below the price by 27%
▲Forward P/E vs sector12.1x vs median 17.6x
▲Piotroski F-score7/9
▲Altman Z4.6 (safe)
▲Net debt / EBITDA-1.4x
▲Analyst target+29% (14 analysts)
Discounted cash flow
Bear
$81
-46%
growth -2% · disc. 13.6% · term. 2.0%
Base
$110
-27%
growth 3% · disc. 12.6% · term. 2.5%
Bull
$144
-4%
growth 6% · disc. 11.6% · term. 3.0%
A DCF starts from trailing free cash flow, so it can overstate value if the last 12 months were unusually strong (or weak). Use the bear case or edit the starting cash flow if so.
Reverse DCFfor context, not a signal
A normal DCF guesses future cash flows and works out a price. A reverse DCF runs it backwards: it starts from today's price and asks how fast free cash flow would have to grow to justify it. It tells you what the market is assuming, not whether the stock is cheap or expensive, and it is not a buy or sell signal. Glossary
Today's price assumes free cash flow grows about 8% a year for 10 years.
Implied
+8%/yr
FCF, last 3 yrs
+21%/yr
FCF, last 5 yrs
-1%/yr
Revenue, last 3 yrs
+3%/yr
Revenue, last 5 yrs
+10%/yr
Same inputs as the DCF above: trailing free cash flow 0.6B, 12.6% discount rate, 2.5% growth after year 10, net cash and today's share count. Actual growth rates are compound annual rates from SEC annual filings through FY2025; "n/a" means too little history or a negative starting year.
Edit assumptions · recalculates instantly
Your value per share–
Free cash flow = operating cash flow − capital spending, trailing 12 months (TTM to 2026-06-30). Growth default: average of 3-year revenue CAGR and latest revenue growth, capped at 30%. Years 6–10 fade linearly to terminal growth. Discount rate = 4.25% risk-free assumption + beta 1.67 × 5% equity premium, kept within 7–13%. Bear: lower growth, +1 pt discount, 2% terminal. Bull: higher growth, −1 pt, 3%.
Multiples vs Health Care
P/E (trailing)
cheaper
sector median 29.9× · 42nd pct
26.2×cheaper
Forward P/E
cheaper
sector median 17.6× · 24th pct
12.1×cheaper
EV / EBITDA
cheaper
sector median 15.8× · 28th pct
12.0×cheaper
Price / sales
cheaper
sector median 3.1× · 42nd pct
2.6×cheaper
Price / book
cheaper
sector median 3.5× · 35th pct
2.5×cheaper
FCF yield
cheaper
sector median 4.1% · 74th pct
5.9%cheaper
Forward EPS $12.43 vs trailing $5.75 (+116% expected growth). Forward P/E uses analysts' next-12-month estimate.
Backlog (remaining performance obligations)
RPO
$1.4B
as of 2025-12-31
vs a year ago
-6%
YoY
× TTM revenue
0.33×
coverage
Contracted revenue not yet recognized, from SEC filings (XBRL tag RevenueRemainingPerformanceObligation).
Quality & financial health
Gross margin
68.0%
Operating margin
13.2%
FCF margin
15.3%
Net margin
10.0%
Return on equity
9.8%
Return on invested capital
12.7%
Net debt / EBITDA
-1.4×
Current ratio
1.4×
Interest cover
10,737.1×
Cash conversion (OCF/NI)
1.8×
Piotroski F-score 7/9 · last two fiscal years
✓ Positive net income✓ Positive operating cash flow✗ Return on assets improved✓ Cash flow above net income✓ Long-term debt / assets fell✓ Current ratio improved✓ No share dilution✗ Gross margin improved✓ Asset turnover improved
Altman Z-score 4.6 (safe zone; above 3.0 = safe, below 1.8 = distress). Not meaningful for banks and insurers.
Analysts
Mean target
$194
+29%
Analysts
14
Buy
Range
$155–$235
low – high
● price · ◆ mean target
Annual history
| FY | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $4.0B | $410.4M | $490.8M |
| 2024 | $4.0B | $421.4M | $622.7M |
| 2023 | $3.9B | $445.1M | $608.1M |
| 2022 | $3.7B | $361.6M | $276.8M |
| 2021 | $4.0B | $772.0M | $771.4M |
| 2020 | $2.5B | $1.8B | $507.3M |
From the company's 10-K filings via SEC XBRL. 3-year revenue CAGR +2.6%.
Earnings
Next report: 2026-10-28 · after close · EPS est 2.78
EstimateActual (beat)Actual (miss)
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-07-29 | 2.60 | 2.64 | +1.7% |
| 2026-04-29 | 2.29 | 2.58 | +12.8% |
| 2026-02-04 | 2.97 | 3.29 | +10.8% |
| 2025-10-29 | 2.41 | 2.61 | +8.4% |
| 2025-07-30 | 2.57 | 2.49 | -3.3% |
| 2025-04-30 | 1.99 | 2.13 | +7.1% |
| 2025-02-05 | 2.45 | 2.44 | -0.4% |
| 2024-10-23 | 2.31 | 2.35 | +1.6% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $1.1B | +4.3% |
| 2026-03-31 | $1.0B | – |
| 2025-12-31 | $1.0B | – |
| 2025-09-30 | $995.7M | – |
| 2025-06-30 | $1.0B | – |
Analyst actions
Baird
PT $162
2026-10-15 · down
Outperform → NeutralPT $162
Leerink Partners
PT $215
2026-10-14 · main
Outperform → OutperformPT $215
Stifel
PT $175
2026-10-09 · main
Buy → BuyPT $175
Evercore ISI Group
PT $155
2026-10-05 · down
Outperform → In-LinePT $155
UBS
PT $189
2026-07-23 · main
Neutral → NeutralPT $189
BMO Capital
PT $209
2026-07-09 · init
→ OutperformPT $209
Insider trades
None
–
None · None
SELL–
Stats refreshed 2026-10-20 18:02:52 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
coteau
Coteau Systematic Strategies publishes stock research and model portfolios. It doesn't manage money or give investment advice. Results are hypothetical unless marked Live. Data: Yahoo Finance (delayed) and SEC EDGAR.